Addressing the post-irradiation hypothalamic-pituitary endocrine abnormalities of brain tumors in pediatric patients

Louloudenia Velentza1*, Maria Tolia2*, Charikleia Christakou3, Michail Nikolaou4, Ioannis Zerdes5, Nikolaos Tsoukalas6, Jiannis Hajiioannou7, Konstantinos Tsanadis2, Georgios Rigas8, Michail Mitsis9, Kyriaki Theodorou2, Kyriaki Pisteou-Gombaki10, Periklis Tsekeris5, George Kyrgias2

1University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece; 2University of Thessaly, School of Health Sciences, Faculty of Medicine, Radiotherapy Department, Larissa, Greece; 3Hygeia Hospital, Oncology unit, Marousi, Athens, Greece; 4Hippokration University Hospital of Athens, Oncology Clinic, Athens, Greece; 5University of Ioannina, School of Health Sciences, Faculty of Medicine, Ioannina, Greece; 6Veterans Hospital (NIMTS), Oncology Department, Athens, Greece; 7Department of Otolaryngology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece; 8Achilopoulio General Hospital, Oncology Clinic, Volos, Greece; 9Department of Surgery, University of Ioannina, School of Health Sciences, Faculty of Medicine, Ioannina, Greece; 10Aristoteleion University of Thessaloniki, AHEPA University Hospital, Radiation Oncology Department, Thessaloniki, Greece

*These authors contributed equally to this study

Summary

Purpose: Hypothalamic-pituitary axis is susceptible to radiotherapy, causing endocrine disorders to childhood cancer survivors. We conducted a systematic review in order to assess the radiation-induced toxicity that leads to hormone secretion abnormalities and their severity in children with brain tumors.

Methods: The data were collected by relevant studies on PubMed and EMBASE. Articles up to December 2016 were included. We selected studies which focused on children patients (<18 yr old) with brain tumors treated with radiotherapy and the consequences for their endocrine system.

Results: Growth hormone (GH) deficiency was the most common post-irradiation abnormality among children cancer survivors, followed by gonadotrophin (GT), thyroid stimulating hormone (TSH), corticotropin (ACTH) and prolactin (PRL) disorders.

Conclusions: The age of the patient, total radiotherapy dose, number of fractions, fraction size and the duration of treatment seem to determine the severity of these disturbances.

Key words: brain, endocrine abnormalities, pediatric, radiotherapy, tumors

Introduction

The central nervous system (CNS) tumors represent the second most frequent childhood malignancy [1]. More specifically, low grade gliomas (LGG) are the CNS malignancies most diagnosed in children, representing a percentage of 35% [2]. Survival rates (5-year survival is almost 80%) appear to be improved over the past years due to the remarkable progress in diagnosis and treatment of children with brain tumors [3].

Although surgical approach represents the gold standard in therapeutic management of these patients, radiotherapy can be selected as the primary treatment when the tumor has central location and multifocal appearance. The radiation field can include the tumor itself or the whole brain and spine. A boost dose is given at the tumor site [4,5].

The most common childhood brain tumors treated with radiotherapy (mostly combined with
surgery) according to the International Classification of Childhood Cancer are the following: ependymomas, choroid plexus tumor, astrocytomas, intracranial and intraspinal embryonal tumors (including medulloblastomas, PNET, medullopithelioma, atypical teratoid/rhabdoid tumor), other gliomas (including oligodendrogliomas, mixed and unspecified gliomas, neuroepithelial glial tumors of uncertain origin), other specified intracranial and intraspinal neoplasms (including pituitary adenomas and carcinomas, craniohypophyseal tumors, pineal parenchymal tumors, neuronal and mixed neuronal-glial tumors, meningiomas) and unspecified intracranial and intraspinal neoplasms [6]. Except for the primary brain tumors, radiotherapy is also delivered for the treatment of head and neck tumors, nasopharyngeal and skull base tumors or prophylactically in cases of acute lymphoblastic leukemia (ALL) and after total-body irradiation before bone marrow transplant.

Radiotherapy schedule for the treatment of childhood CNS tumors include doses >50 Gy (usually 50-60 Gy) whereas prophylactic irradiation doses for ALL range from 18 to 24 Gy [5]. When the hypothalamic-pituitary axis (H-P axis) is involved in the radiation field, multiple endocrine disturbances may occur due to its radio-sensitivity. Almost the 43% of the children treated with radiotherapy for brain tumors will develop at least one endocrine insufficiency. In the Childhood Cancer Survivor Study [9] (CCSS), 43% of children treated for cerebral tumors had one or more endocrinopathies. Consequently, structured follow-up programs for childhood cancer survivors include endocrine assessments. The total dose of radiation, the fraction size, the number of fractions and the total duration of treatment determine the biological impairment of the H-P axis and as a result the appearance of abnormalities in the hormonal secretion by the anterior pituitary. H-P axis’ dysfunction is more vulnerable when a hypofractionated schedule is applied (large fraction size in a short period of time) instead of a schedule with small fraction size and long duration [7].

Methods

A systematic literature review was performed based on database search in PubMed/MEDLINE and EMBASE and included articles up to December 2016. The terms used for the search were ‘Brain Tumors’, ‘Radiotherapy’, ‘Irradiation’, ‘hypothalamus’, ‘hypophysis’, and synonyms combined with one or more of the following: ‘endocrine disorders’, ‘pediatric patients’. Furthermore, these terms were combined with the respective key words for each paragraph. Publications mentioned in the reference list found in the database search and considered suitable were manually searched for. Clinical phase I, II, randomized phase III and IV studies, reviews, meta-analyses and abstracts of important meetings were analyzed. Only articles published in English were included.

Evidence synthesis

The pituitary gland lies in the sella turcica, a cavity of the sphenoid bone in the base of the skull. It is connected anatomically with the hypothalamus through the connecting stalk. The pituitary consists of two lobes that have not only different embryological origin but also a different physiological function: the anterior lobe or adenohypophysis and the posterior lobe or neurohypophysis. The ectoderm and more specifically Rathke’s pouch gives rise to the adenohypophysis whereas the neurohypophysis is derived from the neuroectoderm. The anterior lobe is responsible for the secretion of the following hormones: GH, TSH, the gonadotrophins, including luteinizing hormone (LH) and follicle stimulating hormone (FSH), ACTH and PRL. It produces also the endorphin, a polypeptide which inhibits the perception of pain and the beta-lipotropin, a fat-mobilizing protein hormone. Stimulated hypothalamic neurons secrete either stimulating or inhibiting hormones which are transferred through the hypophyseal portal system to the anterior lobe regulating the release of hormones by the adenohypophysis. The neurohypophysis could be considered as a hypothalamus’ extension. Neurons originating at the supraoptic and paraventricular nuclei of the hypothalamus produce the hormones vasopressin and oxytocin which are transferred through the hypothalamic-hypophyseal tract to the posterior pituitary, where they are stored in axon terminals and are released to the systematic circulation [8,9].

Growth hormone disorders

GH is the first hormone to be affected by brain irradiation for the treatment of tumors and infiltrative diseases such as histiocytosis, sarcoidosis, hemochromatosis, tuberculosis and lymphocytic hypophysitis [4,5,10-15,16]. Children with ALL can also receive CNS prophylactic radiotherapy, including the spine. Considering GH’s important physiological function during childhood, GH deficiency has major clinical consequences for the children treated with radiotherapy including short stature, diminished quality of life, slow muscular development, increased subcutaneous fat and reduced bone density. Furthermore, GH deficiency persisting throughout adulthood appears to aggra-
vate cardiovascular risk profile [17]. Post-irradiation GH abnormalities appear to be both dose- and time-dependent [5,10-12,15]. Total doses of 18 Gy to the hypothalamic-pituitary region cause significant deviation from the normal spontaneous GH secretion as far as quality and quantity are concerned. After a dose of 24 Gy or more, spontaneous secretion is decreased but provoked GH level can be normal and after 27 Gy or more both spontaneous GH secretion and responses to provocative stimuli become progressively less [16]. Although the total dose of radiation is strongly connected with GH abnormalities, there are other factors such as the duration of treatment, fraction size, number of fractions and the age of the patient which are considered to be crucial. GH deficiency may not appear for ten or more years when low doses (18-24 Gy) are used, whereas with higher doses (>30 Gy), GH deficiency can be noticed within 5 years [11,15]. For children treated with radiotherapy to the hypothalamus-pituitary region, the diagnosis of GH deficiency remains a controversial subject. The failure of one stimulation test (Insulin tolerance test or GH-releasing hormone/arginine test) which assesses the maximum secretion of GH after the administration of a secret-analogue, is diagnostically useful. False negative results are possible, rendering stimulation tests unreliable and inaccurate when low doses of radiation have been used [12]. The frequent measurement of serum GH levels (every 20 min for 12-24 hrs), especially during sleep, is an exacting but more accurate process. Peak GH response after a stimulation test (Insulin tolerance test or GH-releasing hormone/arginine test) less than 10μg per liter implies GH deficiency but when the serum concentration is less than 5μg per liter, shows severe deficiency [15]. Insulin growth factor 1 (IGF1) and insulin growth factor binding protein 3 (IGFBP3) serum levels are usually normal despite the presence of post-irradiation GH deficiency and cannot be used as diagnostic criterion to establish the diagnosis [12,15]. Clinical findings which are of great diagnostic importance include stature at least 2.5 standard deviations below the mean normal height for children of the same age, delayed skeletal maturation, growth velocity less than the 25th percentile and eventual height considerably less than parental [18]. GH replacement therapy with recombinant human GH (rhGH) since 1980s is widely used and targets to normalize linear growth and body composition. A probable side effect is impaired glucose tolerance and hyperglycemia, thus measurements of serum glucose levels are required, especially for patients who are most prone to develop insulin resistance [19]. Despite the fact that there is no evidence that GH triggers the development of new malignancies, replacement therapy is usually administered one year after radiotherapy for the majority of tumors and ALL and after two years in case of ependymomas or medulloblastoma [16].

**Luteinizing hormone/follicle-stimulating hormone disorders**

LH’s/FSH’s secretion by the anterior pituitary is triggered by gonadotrophin-releasing hormone (GnRH), a hormone produced by the hypothalamus. Eventually, the unimpaired H-P axis will result in the maturation of germ cells, production of testosterone and estradiol and reproductive capability. Both early and delayed puberty are reported as common complications after radiotherapy used to treat childhood CNS tumors, due to H-P axis’ exposure [4,5,13,14,20,21]. After spinal radiotherapy, the scattered radiation dose is possible to cause primary gonadal disorders. Ovaries are more susceptible to damage than testes due to their anatomical proximity to the spine [4,5]. Precocious puberty is explained by the following pathophysiological mechanism: radiation disrupts the cortical stimulus which normally inhibits the production of GnRH by the hypothalamus during pre-pubertal period [4]. In girls, precocious puberty is characterized by menarche before 10 years of age and breast development before 8 years of age (Tanner’s stage B2), whereas late menarche is described as the onset of menstrual cycles at 16 years or greater. Testicular development (volume >3 ml or length >25mm) before 9 years of age in boys who have not undergone testicular radiotherapy or alkylating chemotherapy is an important clinical finding suggesting precocious puberty (Tanner’s stage G2) [13,20,21]. Secondary sexual characteristics, such as pubic hair are also assessed. Female patients are more vulnerable to central precocious puberty than male patients treated with brain radiotherapy with doses of 18-24 Gy but no difference between the two genders is stated when doses of 25-30 Gy are used [10]. Doses of 18-24 Gy are used as a CNS prophylaxis for patients with ALL, causing early sexual development and menarche [20]. Survivors who experience precocious puberty are more likely to develop hypogonadotropic hypogonadism during adulthood which is also correlated with brain radiotherapy doses >30-50 Gy [4,13]. Apart from the clinical findings, the investigation of central precocious puberty requires the measurement of estradiol/testosterone serum levels and the evaluation of LH/FSH secretion after a stimulation test with GnRH or GnRH agonist [13]. Elevated estradiol/testosterone levels and abundant LH response
are supportive findings of early pubertal development. On the other hand, reduced testosterone, LH/FSH levels in males and prolonged amenorrhea combined with low estradiol levels in females imply gonadotrophin deficiency [13]. Children patients who experience early puberty as a result of radiotherapy are at great risk of growth failure and short stature whereas patients with delayed puberty will probably experience fertility disorders as adults and reduced bone mineral density. As far as treatment is concerned, a LH-releasing hormone analogue is administered to patients who experience precocious puberty while in the setting of delayed puberty replacement treatment with testosterone to males and ethinyl estradiol or 17β-estradiol to females is recommended [10,13,21].

**TSH disorders**

Post-irradiation TSH disorders occur less frequently than GH and LH/FSH ones. Hypothalamus produces TRH, an hormone which is responsible for the secretion of T3 which causes the synthesis of T3 and T4 by the thyroid gland. These hormones are crucial for the regulation of multiple physiological functions including bone growth, reproduction, muscular and cognitive development [22]. Central hypothyroidism, characterized by low free thyroxin (fT4) and reduced (or sometimes normal) TSH serum levels, occurs to a percentage of 23% of patients 4 years after brain radiotherapy with doses >42 Gy [1,5,10,22]. Normal TSH levels after TRH stimulation test indicate hypothalamic dysfunction whereas no response to TRH suggests damage in the anterior pituitary. Almost 20-30% of patients who have received cervical radiation will develop primary hypothyroidism within 5 years after radiotherapy [22]. Primary hypothyroidism (low fT4 and increased TSH levels) is caused by the direct parenchymal and vascular radiation damage to the gland which usually receives not only 70-80% of the posterior spinal field exit dose but also a part of the cranio-cervical radiation dose [23]. TSH deficiency occurs when doses >30-40 Gy are delivered [4,10]. The relatively low incidence of central hypothyroidism (compared to GH and gonadotrophin deficiency) is attributed to three factors: First, the primary damage of the thyroid gland may obscure central malfunction for a long period of time. Secondly, high TSH and low fT4 serum levels could falsely suggest primary hypothyroidism, although they are caused by post-irradiation TSH’s reduced biological activity, a phenomenon called serum alteration. In conclusion, TRH producing cells in the hypothalamus and TSH producing cells in the pituitary are generally not affected by irradiation at least in the short-term, leading to delayed appearance of post-irradiation central hypothyroidism [24]. It is of great importance to mention that doses of 20-29 Gy to the gland increase the risk of secondary carcinoma, usually of papillary type, whereas doses >30 Gy diminish that risk [10]. Recent trials applied the hyperfractioned craniospinal radiotherapy (HFRT) as an alternative to conventionally fractionated craniospinal radiotherapy (CFRT) to children with medulloblastoma. In HFRT, radiation fractions of 1-1.1 Gy are used more than once in the day but the total dose and time of treatment remain the same as CFRT. It was shown that HFRT applies higher doses of radiation to tumor cells than healthy ones and as a result acts protectively and decreases the risk of possible late thyroid dysfunction [24]. Hormone replacement therapy with thyroxine is strongly recommended in order to reinstate hormones’ serum levels and prevent the impact of hypothyroidism on children’s development and cognitive abilities [5,22].

**ACTH disorders**

Radiation-induced ACTH deficiency leads to low synthesis of cortisol and adrenal androgens by the adrenal glands whereas the synthesis of mineralocorticoids is mostly ACTH-independent. Thereby, aldosterone, sodium and potassium serum levels remain normal. Clinical manifestations of adrenal deficiency include weakness, weight loss, poor appetite, nausea, vomiting, abdominal pain, hypotension, hypoglycemia, vascular collapse, low fight or flight response and even adrenal shock. However, partial ACTH deficiency due to dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis is often asymptomatic, but during stressful stimuli, failure to mount a biologically sufficient cortisol response may lead to deleterious consequences and endanger survival.

Radiotherapy with low doses (18-24 Gy) used for the treatment of hematologic malignancies, such as ALL, is not proven to impair the production of ACTH by the pituitary but doses >24 Gy administered for the treatment of brain tumors can cause ACTH deficiency [25]. For the diagnosis of ACTH deficiency, multiple tests are used in clinical practice such as Synacthen test and ITT. Although the ITT has been considered the gold standard when assessing the HPA axis, case reports have demonstrated potential risks using the ITT in children [26]. Therefore, the ACTH test is used in children. The conventional ACTH test using synthetic corticotropin assesses the function of the adrenal cortex. Chronic ACTH deficiency results in atrophy of the adrenal cortex and failure
to respond to exogenous corticotropin. The ACTH test is thus an indirect measurement of the function of the pituitary gland. Brain irradiation may cause ACTH secretory abnormalities if the HP axis has been irradiated. According to a study, 24% of children treated with brain irradiation for CNS or brain tumors were diagnosed with ACTH deficiency [25]. Although ACTH deficiency is not as common as other post-irradiation endocrine disorders, lifelong follow-up is recommended because it may emerge later in life causing life-threatening conditions, if left untreated.

Hyperprolactinemia

Hyperprolactinemia is a rare post-irradiation complication, causing usually insignificant clinical problems. Despite the fact that only 5% of children and adults treated with low radiation doses will develop hyperprolactinemia, adult women radiated with doses $\geq 40$ Gy appear to be more vulnerable [7]. Elevation in prolactin levels reveals hypothalamic dysfunction which is not inhibited by dopamine.

Pathophysiological mechanism of post-irradiation damage

Hypothalamus-pituitary axis’ hormonal failure can be explained by the direct effect of radiation to the DNA of hypothalamic and pituitary’s cells, causing irreparable damage and diminished functionality [7]. In addition, neuroglia cells degenerate and vascular damage occurs, including endothelial loss, blood-brain barrier disruption, edema, hypoxia, vasa vasorum inflammation, thrombosis, hemorrhage and rupture, subsequent fibrosis and thickening of the base membrane [27].

Conclusions

According to the International Classification of Childhood Cancer, brain tumors account for the 23% of malignancies under the age of 15 years, rendering them the first type of childhood solid neoplasms and the second most common oncological disease after hematological malignancies. Although radiotherapy is thriving in the last few years and has substantially contributed to the improvement in prognosis of CNS pediatric tumors, the appearance of post-irradiation complications can be proved devastating for patients’ quality of life. The spectrum of these complications includes learning disabilities, memory and perceptual deficits and hormone deficiencies which are attributed to the impairment of the H-P axis and depend on numerous factors related not only to parameters of radiotherapy (total radiation dose, fraction size, organ/tissue volume) but also to the host (gender, age, developmental status). The appropriate assessment and early confrontation of endocrine failure are considered requisites for the normal development of childhood cancer survivors and thus long-term follow-up guidelines have been published [4,9,13,20,25] in order to be applied in everyday clinical practice. As far as the GH is concerned, follow-up includes the evaluation of nutritional status, height and weight every six months and yearly after the growth completion, the Tanner staging every six months until complete pubertal development and the control of thyroid function. Weight below the 3rd percentile in growth chart and retarded bone age in an x-ray of the wrist are signs of poor growth velocity. Physical examination, evaluation of pubertal progress (Tanner staging, testicular volume by Prader orchimeter) every year and measurements of LH/FSH, testosterone and estradiol serum levels are recommended for the evaluation of precocious puberty and gonadotrophin deficiency. The follow-up of thyroid function requires yearly physical examination (weight, height, hair and skin) and measurement of TSH and fT4 but more frequent screening is proposed during periods of rapid growth. Finally, for patients irradiated in the H-P axis with doses $\geq 30$ Gy yearly evaluation for ACTH insufficiency is suggested. The sudden mental derangement could possibly imply primary tumor recurrence or appearance of secondary tumor and thus clinical assessment and imaging of the region should be performed. The applied treatment strategy (extent of surgical resection, RT doses and radiation field, possible administration of chemotherapeutic agents), the histological type and location of the tumor should be meticulously registered in the patients’ medical history which constitutes a crucial asset during the long-term follow-up. In the past few years, 3-dimensional imaging techniques have been proven veritably valuable to the more precise H-P axis dosimetric estimation and consequently to the proper evaluation of potential hormone deficiencies. In addition, recently applied hyperfractionated radiotherapy techniques reduce the radiation exposure of the normal brain parenchyma but meanwhile maximize the dose which the tumor itself receives.

The constant progress in brain tumors treatment strategies enhances the survival rates and triggers the need for early diagnosis of post-irradiation late effects and immediate therapeutic intervention. H-P axis dysfunction numbers among
the most serious abnormalities for childhood brain tumors survivors and requires more thorough understanding of the pathophysiology of the damage in order to achieve not only timely diagnosis but also to organize an individualized long-term follow-up program for each patient. Collaboration of multiple medical specialties, such as pediatrician, radiation oncologist and endocrinologist is crucial for the best confrontation of the challenges posed to the children patients and their families.

Conflict of interests

The authors declare no conflict of interests.

References


JBUON 2017; 22(5): 1245